Endothelin-1-, Endothelin-A-, and Endothelin-B-Receptor Expression Is Correlated with Vascular Endothelial Growth Factor Expression and Angiogenesis in Breast Cancer
- 1 April 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (7), 2393-2400
- https://doi.org/10.1158/1078-0432.ccr-03-0115
Abstract
Purpose: Endothelin-1 (ET-1) and its receptors (ETAR and ETBR), referred to as the endothelin (ET) axis, are overexpressed in breast carcinomas, and influence tumorigenesis and tumor progression by various mechanisms, including angiogenesis. The objective of the study was to clarify if expression of the ET axis participates in angiogenesis of breast carcinoma Experimental Design: We analyzed expression of ET-1, ETAR, ETBR, and vascular endothelial growth factor (VEGF) immunohistochemically in 600 tissue array specimens from 200 paraffin-embedded breast carcinomas performing tissue microarray technology. Microvessel density (MVD) was determined by counting microvessels (identified by factor VIII) in each core specimen. Results: Moderate or strong immunostaining was observed for ET-1 in 25.4%, for ETAR in 43.7%, and for ETBR in 22.2% of breast carcinomas. Of all cases, 44.7% showed significant expression of VEGF. MVD varied between different tumor specimens (range, 0–80; median, 17). We observed a statistically significant correlation between MVD and ET expression status with higher MVD in ET-positive tumors. Moreover, expression of VEGF was found more frequently in tumors with overexpression of the ET axis (each P < 0.001). Staining of VEGF was correlated positively with MVD Conclusions: These results indicate that increased ET-1, ETAR, and ETBR expression is associated with increased VEGF expression and higher vascularity of breast carcinomas and, thus, could be involved in the regulation of angiogenesis in breast cancer. Our findings provide evidence that the expression pattern of the ET-axis and in particular of ETAR may have clinical relevance in future antiangiogenic targeted therapies for breast cancer.Keywords
This publication has 32 references indexed in Scilit:
- Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1α in Ovarian Carcinoma CellsJournal of Biological Chemistry, 2002
- Role of Endothelin-1 in Neovascularization of Ovarian CarcinomaThe American Journal of Pathology, 2000
- Endothelins Are AngiogenicJournal of Cardiovascular Pharmacology, 2000
- Raised endothelin 1 levels in patients with colorectal liver metastasesBritish Journal of Surgery, 1998
- Angiogenesis as a Predictor of Long-term Survival for Patients With Node-Negative Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysisThe Journal of Pathology, 1995
- Enhancement of Tumor Growth and Vascular Density by Transfection of Vascular Endothelial Cell Growth Factor Into MCF-7 Human Breast Carcinoma CellsJNCI Journal of the National Cancer Institute, 1995
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- Hypoxia induces endothelin gene expression and secretion in cultured human endothelium.Journal of Clinical Investigation, 1991
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988